October 4, 2024 02:27 PM EDT
Pharma
FDA+

EMA re­views hair loss prod­ucts fol­low­ing con­cerns about sui­ci­dal thoughts

Nicole DeFeudis

Editor

The Eu­ro­pean Med­i­cines Agency is look­ing more close­ly at med­i­cines used to treat hair loss and a con­di­tion caused by an en­larged prostate over con­cerns …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Biotech's third quar­ter was rel­a­tive­ly bright — with a few caveats

RSV vac­cines off to a slug­gish start in US this sea­son, with vol­umes be­hind 2023

Sanofi sells rare dis­ease drug En­jay­mo to Recor­dati for $825M up­front

WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port

J&J dis­con­tin­ues mid-stage dengue study, cit­ing de­pri­or­i­ti­za­tion of com­mu­ni­ca­ble dis­ease work

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times